No­vavax snags Ben Machielse for CMC and pro­motes a trio of staffers; Mar­ty Du­vall lands an­oth­er CEO post at On­copep­tides

No­vavax has been mak­ing waves re­cent­ly by se­cur­ing a $384 mil­lion com­mit­ment from CEPI to cov­er R&D and man­u­fac­tur­ing for its Covid-19 vac­cine while al­so spend­ing $167 mil­lion on a 150,000 square-foot fa­cil­i­ty. The Mary­land biotech con­tin­ues to shore up its lead­er­ship team as well, bring­ing in Ben Machielse as their EVP of CMC just a cou­ple weeks af­ter nab­bing As­traZeneca vet Fil­ip Dubrovsky as their new CMO. Machielse was pres­i­dent and CEO of Vtesse from 2014-17, and be­fore that, he al­so spent more than 11 years at Med­Im­mune and was EVP of op­er­a­tions for the back half of his tenure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.